TAK-988 / Takeda - LARVOL DELTA

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: Takeda; N=156 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants (clinicaltrials.gov) - P1; N=156; Not yet recruiting; Sponsor: Takeda; Trial completion date: Jan 2021 ➔ Apr 2022; Trial primary completion date: Jan 2021 ➔ Apr 2022

Clinical • Trial completion date • Trial primary completion date

[VIRTUAL] TAK-988, an orally available orexin 2 receptor-selective agonist, ameliorates narcolepsy-like symptoms in an orexin neuron-ablated mouse model of narcolepsy (ESRS 2020) - "TAK-988 significantly increased wakefulness and ameliorated both fragmentation of wakefulness and cataplexy-like episodes in orexin/ataxin-3 mice during active phase. TAK-988 has the potential to treat the cardinal symptoms of NT1 such as excessive daytime sleepiness and cataplexy."

Cataplexy • Excessive Daytime Sleepiness • Narcolepsy • Sleep Disorder

[VIRTUAL] Discovery of a novel, orally available orexin 2 receptor-selective agonist, TAK-988, as a potential therapeutic drug for narcolepsy. (EAN 2020) - "The orally available TAK-988, OX2R agonist may have potential as a new treatment option for individuals with NT1 as well as other hypersomnia disorders with normal orexin levels."

Sleep Disorder

[VIRTUAL] Discovery of a novel, orally available orexin 2 receptor-selective agonist, TAK-988, as a potential therapeutic drug for narcolepsy. (EAN 2020) - No abstract available

Sleep Disorder

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants (clinicaltrials.gov) - P1; N=156; Not yet recruiting; Sponsor: Takeda; Trial completion date: Aug 2020 ➔ Jan 2021; Initiation date: Apr 2020 ➔ Nov 2020; Trial primary completion date: Aug 2020 ➔ Jan 2021

Clinical • Trial completion date • Trial initiation date • Trial primary completion date

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants (clinicaltrials.gov) - P1; N=156; Not yet recruiting; Sponsor: Takeda; Initiation date: Oct 2019 ➔ Mar 2020

Clinical • Trial initiation date